• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AtriCure (ATRC) Momentum Meets A Pricey Narrative On $47 Fair Value

    Simply Wall St·09/09/2026 03:30:56
    Listen to the news

    AtriCure (ATRC) has drawn fresh attention after a strong run in its shares over the past 3 months, with the price recently closing at $53.73 and year-to-date returns remaining positive.

    AtriCure’s sharp 29.03% 1 month share price return and powerful 89.12% 3 month share price return point to building momentum, while the 52.86% 1 year total shareholder return contrasts with a 5 year total shareholder return that remains down 28.24%.

    Scan how AtriCure’s momentum compares with other high quality shares by reviewing the hand picked 49 high quality undervalued stocks that combine stronger balance sheets with robust cash generation.

    AtriCure’s jump over the past quarter can look like a clean vote of confidence in a growing medical devices business, or a rush of optimism chasing momentum. The valuation now needs a closer look.

    Most Popular Narrative: 14.3% Overvalued

    AtriCure’s most followed valuation narrative points to a fair value of $47.00, which sits below the recent $53.73 close and implies a premium that hinges on ambitious growth and margin expectations.

    Positive volume trends from new product launches, combined with operational efficiencies (evidenced by SG&A and R&D growth below revenue growth), are driving operating leverage, which should improve net margins and profitability as the business continues to scale.

    Read the complete narrative.

    Want to see what is baked into that $47.00 fair value? The narrative leans on strong top line expansion, a step change in profitability, and a rich future earnings multiple. Curious which specific growth and margin assumptions need to hold for that valuation to stack up against today’s price?

    Result: Fair Value of $47.00 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    Still, two pressure points could unsettle that AtriCure narrative: rising AtriClip competition and the risk that costly trials do not translate into stronger profitability.

    Find out about the key risks to this AtriCure narrative.

    Another View: What AtriCure’s Sales Multiple Is Telling You

    While the AtriCure narrative leans on earnings-driven fair value, the current P/S of 4.8x paints a different picture. That level is above both the US Medical Equipment industry on 3x and the stock’s fair ratio of 4.2x, which hints at less room for error if growth or margins fall short.

    For investors weighing that gap between current P/S and the fair ratio, the key question is whether today’s premium reflects durable progress or optimism that could fade if expectations are not met.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGM:ATRC P/S Ratio as at Sep 2026
    NasdaqGM:ATRC P/S Ratio as at Sep 2026

    Next Steps

    Mixed signals around AtriCure’s recent surge and longer term record can spark debate, so move quickly, pull up the underlying data, and weigh both the upside and the caution flags by reviewing the 2 key rewards and 1 important warning sign

    Looking for more investment ideas beyond AtriCure?

    Do not stop at AtriCure. Use the wider market to stress test your thinking and uncover opportunities that fit your risk, income, and quality preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.